Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation For Treatment Of zygomycosis By U.S.
Basilea Pharmaceutica AG announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of zygomycosis (also known as mucormycosis), a life-threatening fungal infection. Basilea announced on May 28, 2013 that the FDA granted isavuconazole orphan drug designation for the treatment of invasive aspergillosis. An FDA orphan drug designation provides several benefits to the sponsor including a seven-year market exclusivity in the United States dating from product approval. Isavuconazole also has FDA fast track status, which has the goal of getting important new drugs to patients with life-threatening conditions as quickly as possible.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG says Swissmedic approves Zevtera
- Basilea Pharmaceutica AG reports granting of U.S. orphan drug designation to isavuconazole for treatment of invasive candidiasis
- Basilea Pharmaceutica AG receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis
- Basilea Pharmaceutica AG confirms FY 2014 guidance
- Share this
- Digg this